Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

2.

Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.

3.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

4.

Next Day Mood Is Affected by Ability to Recover From Work.

5.

GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot